Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration.

Publication Type:

Journal Article

Source:

Cancer chemotherapy and pharmacology, Volume 75, Issue 1, p.67-75 (2015)

Keywords:

Adolescent, Adult, Aged, Antimetabolites, Research Trials Office Core Facility - Biostatistics Service, Antineoplastic, Child, Cohort Studies, Half-Life, hematopoietic stem cell transplantation, Humans, Immunosuppression, Immunosuppressive Agents, Leukemia, Myeloid, Lymphocyte Count, Lymphopoiesis, Middle Aged, Models, Biological, Myeloproliferative Disorders, Reproducibility of Results, Retrospective Studies, Transplantation Conditioning, Vidarabine Phosphate, Young Adult

Abstract:

Quantitative relationships between 9-β-D-arabinofuranosyl-2-fluoroadenine (F-ara-A) concentrations and lymphosuppression have not been reported, but would be useful for regimen design. A population pharmacokinetic/pharmacodynamic model was constructed in this study using data from 41 hematopoietic cell transplant (HCT) recipients conditioned with busulfan in combination with fludarabine (total dose 120 mg/m², Protocol 1519) or with fludarabine (total dose 250 mg/m²) with rabbit antithymocyte globulin (rATG, Protocol 2041).